Evogliptin tartrate

Overview

Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy . Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Autophagy | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Dipeptidyl Peptidase | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-117985B
• CAS No.: 1222102-51-3
• Molecular Formula: C23H32F3N3O9
• Molecular Weight: 551.51
• Purity: 98.11%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (4.53 mM); Clear solution
• Availability: In-stock

Source

Original product source